A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of Nalbuphine ER (NAL ER) tablets in subjects
diagnosed with Idiopathic Pulmonary Fibrosis (IPF) and evaluate it's treatment of cough in
these patients. This is a two-treatment, 2-period crossover study. Subjects will be
randomized in Treatment Period 1 to either NAL ER or matching placebo and evaluate for
approximately 21 days. After completion of the first phase, subjects who received NAL ER will
crossover to placebo and subjects who received placebo will crossover to NAL ER to complete
Treatment Period 2.